Waldencast 향후 성장
Future 기준 점검 0/6
Waldencast은 연간 수입과 매출이 각각 62.4%와 6% 증가할 것으로 예상되고 EPS는 연간 64.9%만큼 증가할 것으로 예상됩니다.
핵심 정보
62.4%
이익 성장률
64.85%
EPS 성장률
| Personal Products 이익 성장 | 33.6% |
| 매출 성장률 | 6.0% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 29 Apr 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • May 04
WALD: Brand Strength And Injectables Launch Will Support Future Share Rebound
Analysts have trimmed their average price target on Waldencast from about $3.08 to roughly $1.87, reflecting recent EBITDA and sales shortfalls, slower growth and higher costs. At the same time, they point to ongoing brand strength and potential upside from the Saypha injectables launch.
내러티브 업데이트 • Apr 20
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.
내러티브 업데이트 • Apr 05
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.내러티브 업데이트 • Mar 22
WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.내러티브 업데이트 • Mar 07
WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.내러티브 업데이트 • Feb 21
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.내러티브 업데이트 • Feb 06
WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.내러티브 업데이트 • Jan 23
WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.분석 기사 • Jan 10
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc ( NASDAQ:WALD ) shareholders won't be pleased to see that the share price has had a very rough month...내러티브 업데이트 • Jan 07
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.내러티브 업데이트 • Dec 14
WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.내러티브 업데이트 • Nov 28
WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.분석 기사 • Nov 26
Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 26
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc ( NASDAQ:WALD ) shares have continued their recent momentum with a 33% gain in the last month alone. Not...Seeking Alpha • Sep 23
Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Summary Waldencast faces ongoing challenges with slowing revenue growth, heavy debt, and profitability concerns despite recent margin expansion. WALD's acquisition of Novaestiq aims to double its addressable market by entering the U.S. dermal filler space under the Obagi brand, with risk-mitigating deal terms. Recent trading updates show Milk Makeup's U.S. growth via Ulta and Amazon, while Obagi excels internationally, but overall FY 2025 guidance has been lowered. Despite a potential 20% upside to the $2.50–2.70 range, I maintain a 'Hold' rating as structural issues and dilution risks persist. Read the full article on Seeking Alpha분석 기사 • Aug 21
Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...내러티브 업데이트 • Aug 21
Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.분석 기사 • May 14
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Apr 09
It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Waldencast plc ( NASDAQ:WALD ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
새로운 내러티브 • Mar 30
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.분석 기사 • Aug 13
Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 26% in the last...Seeking Alpha • Jun 28
Waldencast Plc: Investors Continue To Demand More Growth
Summary Waldencast plc provides 'Milk Makeup' & 'Obagi' brands in beauty & wellness industry. Q1 2024 saw 21% revenue growth, improved profitability trends, and increased adjusted EBITDA for Waldencast. Fiscal 2024 guidance includes expectations of continued growth through e-commerce, international sales, and brand partnerships. Read the full article on Seeking Alpha분석 기사 • Jun 19
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • May 11
Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 29% in the last...분석 기사 • Apr 07
Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Key Insights Waldencast's estimated fair value is US$14.29 based on 2 Stage Free Cash Flow to Equity Waldencast's...분석 기사 • Dec 14
Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
How far off is Waldencast plc ( NASDAQ:WALD ) from its intrinsic value? Using the most recent financial data, we'll...Seeking Alpha • Aug 11
Waldencast Acquisition reports Q2 results; reaffirms FY22 guidance
Waldencast Acquisition press release (NASDAQ:WALD): Q2 Revenue of $77.1M (+23.8% Y/Y) beats by $11.6M. Pro Forma Adjusted EBITDA was $21.9M an increase of 38.6% reaching a Pro Forma Adjusted EBITDA margin of 28.4%. The company reaffirms its previously issued outlook for Fiscal 2022 provided on November 15, 2021: Net Sales of $256.3M vs. consensus of $256.00M; gross profit of $189.8M; adjusted EBITDA of $49.6M.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2027 | 306 | -73 | N/A | N/A | 4 |
| 12/31/2026 | 282 | -76 | N/A | N/A | 4 |
| 12/31/2025 | 272 | -230 | 66 | -13 | N/A |
| 9/30/2025 | 273 | -216 | 26 | -11 | N/A |
| 6/30/2025 | 275 | -202 | -14 | -9 | N/A |
| 3/31/2025 | 274 | -122 | -13 | -9 | N/A |
| 12/31/2024 | 274 | -42 | -12 | -9 | N/A |
| 9/30/2024 | 257 | -57 | -19 | -17 | N/A |
| 6/30/2024 | 240 | -71 | -27 | -25 | N/A |
| 3/31/2024 | 229 | -80 | -29 | -27 | N/A |
| 12/31/2023 | 218 | -90 | -32 | -30 | N/A |
| 9/30/2023 | 256 | -156 | N/A | N/A | N/A |
| 6/30/2023 | 275 | -131 | -103 | -99 | N/A |
| 3/31/2023 | 221 | -113 | -96 | -93 | N/A |
| 12/31/2022 | 166 | -96 | -88 | -85 | N/A |
| 9/30/2022 | 73 | -19 | N/A | N/A | N/A |
| 6/30/2022 | N/A | -6 | -2 | -2 | N/A |
| 3/31/2022 | N/A | -10 | -1 | -1 | N/A |
| 12/31/2021 | N/A | -14 | -1 | -1 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: WALD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: WALD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: WALD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: WALD 의 수익(연간 6%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: WALD 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: WALD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/14 18:07 |
| 종가 | 2026/05/14 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Waldencast plc는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Olivia Tong Cheang | Raymond James & Associates |